title: Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.
abstract: Osteonecrosis is a disabling complication of treatment for pediatric acute lymphoblastic leukemia, and much effort has been made to predict which patients are prone to develop this disease. Multiple clinical and genetic factors have already been identified as being associated with osteonecrosis; however, a prediction model that combines pretreatment genetic biomarkers and clinical factors has not yet been designed. Such a prediction model can only be developed with continuing international collaborations and research efforts, including large genome-wide association studies.
authors.affiliation: Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands.|Princess Maxima Centre for Pediatric Oncology, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
authors.forename: Marissa A H
authors.initials: MA
authors.lastname: den Hoed
authors.affiliation: Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands.|Princess Maxima Centre for Pediatric Oncology, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
authors.forename: Saskia M F
authors.initials: SM
authors.lastname: Pluijm
authors.affiliation: Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
authors.forename: André G
authors.initials: AG
authors.lastname: Uitterlinden
authors.affiliation: Princess Maxima Centre for Pediatric Oncology, Lundlaan 6, 3584 EA, Utrecht, The Netherlands.
authors.forename: Rob
authors.initials: R
authors.lastname: Pieters
authors.affiliation: Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital Rotterdam, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, The Netherlands. m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl.|Princess Maxima Centre for Pediatric Oncology, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl.
authors.forename: Marry M
authors.initials: MM
authors.lastname: van den Heuvel-Eibrink
mesh_terms: D055419:Bone Morphogenetic Protein 7 / Q000235:genetics; D002648:Child; D005819:Genetic Markers; D055106:Genome-Wide Association Study; D018398:Homeodomain Proteins / Q000235:genetics; D006801:Humans; D008954:Models, Biological; D010020:Osteonecrosis / Q000175:diagnosis* / Q000209:etiology / Q000235:genetics*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000235:genetics*; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics; D012307:Risk Factors; D025521:Tumor Suppressor Proteins / Q000235:genetics; D000098551:Prospero-Related Homeobox 1 Protein
chemical_list: C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; C548929:GRIN3A protein, human; D005819:Genetic Markers; D018398:Homeodomain Proteins; D017395:Plasminogen Activator Inhibitor 1; D016194:Receptors, N-Methyl-D-Aspartate; C051321:SERPINE1 protein, human; D025521:Tumor Suppressor Proteins; D000098551:Prospero-Related Homeobox 1 Protein